ABMA
Based on 1 publication(s) in Google Scholar
ABMA is a broad-spectrum inhibitor of intracellular toxins and pathogens. ABMA efficiently protects cells against various toxins and pathogens including viruses, intracellular bacteria and parasite. ABMA selectively acts at host cell late endosomes rather than targeting toxin or pathogen itself. ABMA has broad-spectrum anti-infection activity.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.50%
- CAS No.: 332108-65-3
- Formule: C18H24BrNO
- Masse moléculaire:350.29
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) ABMA
MoreVoir tous les produits spécifiques à Isoform Parasite
More
Activité biologique
Description
IC50 & Target
|
Leishmania |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | CC50 |
276.8 μM
Compound: ABMA
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by Alamar blue assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by Alamar blue assay
|
[PMID: 31413797] |
| A549 | EC50 |
62.9 μM
Compound: ABMA
|
Cytoprotection activity against diphtheria toxin-induced cytotoxicity against human A549 cells assessed as effect on protein synthesis incubated for 20 hrs followed by replacement of [14c]-Leucine containing medium and measured after 4 hrs by liquid scint
Cytoprotection activity against diphtheria toxin-induced cytotoxicity against human A549 cells assessed as effect on protein synthesis incubated for 20 hrs followed by replacement of [14c]-Leucine containing medium and measured after 4 hrs by liquid scint
|
[PMID: 31413797] |
In Vitro
ABMA protects cells against four bacterial toxins (Corynebacterium diphtheriae (DT; EC50 of 62.9 μM), Bacillus anthracis (LT), Clostridium difficile toxin B (TcdB; EC50 of 73.3 μM), Clostridium sordellii lethal toxin (TcsL; EC50 of 86.7 μM)), three viruses (Ebola (EC50 of 3.3 μM), rabies (EC50 of 19.4 μM), dengue-4 virus ( EC50 of 8.2 μM)), two species of Chlamydiales intracellular bacteria (Simkania negevensis and Chlamydia trachomatis), and the parasite Leishmania infantum (EC50 of 7.1 μM) at micromolar level[1].
In A549 cells, ABMA treatment induces a decrease in ricin cytotoxicity with an EC50 of 3.8 μM, and a protection factor (R) at 30 μM ranging from 5 to 10. ABMA retained almost 100% of its biological activity against ricin-induced cytotoxicity up to six days[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Pathogen-free female BALB/c mice (6 week-old) with ricin[1]
-
Dosage:2 mg/kg, 20 mg/kg, 200 mg/kg
-
Administration:Intraperitoneal injection
-
Result:A statistically significant protection according to survival curves was observed with a single ip dose of 2 mg/kg. The 20 mg/kg dose fully protected animals through to day 21. The 200 mg/kg dose resulted in 80% of protection of mice against ricin challenge with a single animal succumbing on day 15.
Chemical Information
-
CAS No. 332108-65-3
-
Appearance Solid
-
Masse moléculaire 350.29
-
Formule C18H24BrNO
-
Color White to off-white
-
SMILES
COC1=CC=C(Br)C=C1CNC2(C3)CC4CC3CC(C4)C2
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (1)
-
Journal Impact Factor
-
Most Recent
Solvant et solubilité
In Vitro:
DMSO : 125 mg/mL (356.85 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 6.25 mg/mL (17.84 mM); Clear solution
This protocol yields a clear solution of ≥ 6.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (62.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 6.25 mg/mL (17.84 mM); Clear solution
This protocol yields a clear solution of ≥ 6.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (62.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (278 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Wu Y, et al. ABMA, a small molecule that inhibits intracellular toxins and pathogens by interfering with late endosomal compartments. [Content Brief]
[2]. Wu Y, et al. DABMA: A Derivative of ABMA with Improved Broad-Spectrum Inhibitory Activity of Toxins and Viruses. ACS Med Chem Lett. 2019 Jul 2;10(8):1140-1147. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.8548 mL | 14.2739 mL | 28.5478 mL | 71.3694 mL |
| 5 mM | 0.5710 mL | 2.8548 mL | 5.7096 mL | 14.2739 mL | |
| 10 mM | 0.2855 mL | 1.4274 mL | 2.8548 mL | 7.1369 mL | |
| 15 mM | 0.1903 mL | 0.9516 mL | 1.9032 mL | 4.7580 mL | |
| 20 mM | 0.1427 mL | 0.7137 mL | 1.4274 mL | 3.5685 mL | |
| 25 mM | 0.1142 mL | 0.5710 mL | 1.1419 mL | 2.8548 mL | |
| 30 mM | 0.0952 mL | 0.4758 mL | 0.9516 mL | 2.3790 mL | |
| 40 mM | 0.0714 mL | 0.3568 mL | 0.7137 mL | 1.7842 mL | |
| 50 mM | 0.0571 mL | 0.2855 mL | 0.5710 mL | 1.4274 mL | |
| 60 mM | 0.0476 mL | 0.2379 mL | 0.4758 mL | 1.1895 mL | |
| 80 mM | 0.0357 mL | 0.1784 mL | 0.3568 mL | 0.8921 mL | |
| 100 mM | 0.0285 mL | 0.1427 mL | 0.2855 mL | 0.7137 mL |
ABMA Related Classifications
HY-124801 Related Classifications
Powered by Bioz